Cocoon Biotech, Inc., was founded in 2013 to bring the freedom of living a healthy productive life to patients worldwide. Cocoon Biotech is developing a drug-delivery platform based on formulations of fibroin, a protein derived from the cocoon of the silkworm (Bombyx mori).  Silk fibroin is a biocompatible protein that has been used for decades as a suture material; however, recent advances in our understanding of fibroin biochemistry has allowed expansion of the versatility of the material into alternate physical formats such as spheres and hydrogels loaded with active drug substances.

Cocoon’s first product is silk fibroin formulated with a small molecule that targets pain and inflammation.  Cocoon is leveraging silk fibroin as a novel biomaterial for the stability and delivery of therapeutics across human health and animal health.